Nuveen Asset Management LLC Lowers Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

Nuveen Asset Management LLC lessened its position in Kodiak Sciences Inc. (NASDAQ:KOD) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 139,688 shares of the company’s stock after selling 5,761 shares during the quarter. Nuveen Asset Management LLC owned about 0.27% of Kodiak Sciences worth $1,390,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in KOD. PNC Financial Services Group Inc. raised its position in Kodiak Sciences by 1,501.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock valued at $32,000 after purchasing an additional 2,988 shares during the period. American Century Companies Inc. lifted its position in Kodiak Sciences by 6.2% during the 4th quarter. American Century Companies Inc. now owns 59,967 shares of the company’s stock worth $597,000 after acquiring an additional 3,515 shares during the period. US Bancorp DE acquired a new stake in Kodiak Sciences during the 4th quarter worth approximately $40,000. Bank of New York Mellon Corp lifted its holdings in shares of Kodiak Sciences by 5.3% in the 4th quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company’s stock valued at $976,000 after buying an additional 4,927 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Kodiak Sciences by 2.9% in the 4th quarter. Northern Trust Corp now owns 269,597 shares of the company’s stock valued at $2,682,000 after buying an additional 7,678 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Trading Up 9.4%

Shares of Kodiak Sciences stock opened at $3.94 on Wednesday. Kodiak Sciences Inc. has a twelve month low of $1.92 and a twelve month high of $11.60. The stock has a market capitalization of $207.89 million, a P/E ratio of -1.08 and a beta of 2.42. The business’s fifty day moving average price is $3.35 and its 200 day moving average price is $5.40.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.20). As a group, sell-side analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.